CSL Limited (CSLLY)

Market Cap	52.01B -37.4%
Revenue (ttm)	15.41B +1.2%
Net Income	1.40B -49.2%
EPS	2.86 -49.5%
Shares Out	n/a
PE Ratio	37.26
Forward PE	14.95
Dividend	1.39 (2.57%)
Ex-Dividend Date	Mar 11, 2026

Volume	12,335
Average Volume	170,035
Open	53.89
Previous Close	53.00
Day's Range	53.67 - 54.16
52-Week Range	52.00 - 89.71
Beta	0.28
RSI	32.38
Earnings Date	Feb 11, 2026

About CSL Limited

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascul...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1916
• Employees: 29,904
• Stock Exchange: OTCMKTS
• Ticker Symbol: CSLLY

Financial Performance

In fiscal year 2025, CSL Limited's revenue was $15.56 billion, an increase of 5.12% compared to the previous year's $14.80 billion. Earnings were $3.00 billion, an increase of 13.63%.